+435.4%
GEV vs MRNA
+78.0%
+357.4%
-40.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -7.5% | -2.2% | -5.4% | -7.5% |
| 7D | -12.9% | -12.7% | -0.2% | -12.6% |
| 30D | -24.4% | -20.7% | -3.8% | -23.9% |
| 3M | -27.6% | +46.3% | -73.8% | -28.4% |
| 6M | -31.7% | +305.2% | -336.9% | -38.1% |
| YTD | +7.3% | +561.2% | -554.0% | -9.8% |
| 1Y | +25.6% | +772.1% | -746.5% | +1.8% |
| All | +435.4% | +78.0% | +357.4% | +400.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling